Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 32NIH 14INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 5CNS 5Breast 5Genitourinary 4Thoracic 3Gynecologic 3Gastrointestinal 3Dermatologic 3Sarcoma 2Plasma cell 2Lymphoid 2Tumor-Agnostic 1Other solid neoplasm 1Myeloid 1Head & Neck 1

Conditions

Melanoma 3

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cisplatin 15Fluorouracil 14Cyclophosphamide 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × sargramostim × Dermatologic × Clear all
NCT04382664 2025-01-14

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Ultimovacs ASA

Phase 2 Completed
156 enrolled 11 charts
Dermatologic

Melanoma

NCT02275416 2024-12-16

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Ultimovacs ASA

Phase 1/2 Completed
12 enrolled
Dermatologic

Melanoma

NCT00769704 2016-07-13

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

BioVex Limited

Phase 3 Completed
437 enrolled 19 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡